Home » Stocks » GTHX

G1 Therapeutics, Inc. (GTHX)

Stock Price: $23.39 USD 0.32 (1.39%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
After-hours: $23.50 +0.11 (0.47%) Mar 2, 7:58 PM
Market Cap 959.61M
Revenue (ttm) 45.29M
Net Income (ttm) -99.25M
Shares Out 37.88M
EPS (ttm) -2.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $23.39
Previous Close $23.07
Change ($) 0.32
Change (%) 1.39%
Day's Open 22.95
Day's Range 22.48 - 23.50
Day's Volume 2,273,899
52-Week Range 8.80 - 37.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 18 hours ago

- Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutio...

Benzinga - 6 days ago

Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 28.72% year over year to ($0.67), which be...

GlobeNewsWire - 6 days ago

- G1's COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March -

GlobeNewsWire - 1 week ago

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a ...

Benzinga - 2 weeks ago

G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bon...

GlobeNewsWire - 2 weeks ago

- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy -

GlobeNewsWire - 3 weeks ago

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1's Chief Executive Officer Jack ...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors' and officers' possi...

Seeking Alpha - 1 month ago

G1 Therapeutics has a PDUFA date coming up on February 15, 2021 for its first therapy, trilaciclib in SCLC. G1's stock has moved hugely upward over the last few months as investors begin to an...

GlobeNewsWire - 1 month ago

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Baile...

GlobeNewsWire - 1 month ago

- Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) -

GlobeNewsWire - 2 months ago

Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader (SERD) rintodestrant for ER+, HER2- breast cancer Company also presents updated mono...

Seeking Alpha - 3 months ago

GTHX stock is depressed but I don't see any reason. PDUFA of Feb. 15, 2021, is a major catalyst.

GlobeNewsWire - 3 months ago

RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer J...

Benzinga - 3 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: CAR, BH, GSKY, KROS, ORGO, REYN, WTRH
GlobeNewsWire - 3 months ago

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data f...

GlobeNewsWire - 3 months ago

RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Baile...

Seeking Alpha - 3 months ago

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and confere...

GlobeNewsWire - 4 months ago

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that four presentations highlighting th...

GlobeNewsWire - 5 months ago

- Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors

GlobeNewsWire - 5 months ago

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that two presentations highlightin...

GlobeNewsWire - 6 months ago

RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that the company will participate ...

Seeking Alpha - 6 months ago

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: BYSI, KPTI, URGN
Seeking Alpha - 6 months ago

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: BYSI, KPTI, URGN
GlobeNewsWire - 6 months ago

- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration - Priority Review for trilaciclib is based on positive data from three randomized clinical trials showin...

Seeking Alpha - 6 months ago

G1 Therapeutics' (GTHX) CEO Mark Velleca on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

- Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC) - Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch - Partnership for trila...

GlobeNewsWire - 6 months ago

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark V...

GlobeNewsWire - 7 months ago

RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that it will host a webcast and con...

GlobeNewsWire - 7 months ago

- G1 to receive $20 million upfront payment, sales royalties and potential milestone payments of up to $290 million for commercialization of lerociclib in the U.S., Europe, Japan

GlobeNewsWire - 8 months ago

- Partnership leverages Boehringer Ingelheim’s oncology expertise to lead trilaciclib SCLC launch sales engagements - G1 to retain full development and commercialization rights and book reven...

Seeking Alpha - 8 months ago

G1 Therapeutics Has Multiple Roadmaps To A Multi-Billion Dollar Market Cap

GlobeNewsWire - 8 months ago

- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments - Genor to lead clinical development, regulatory submissions and commercializati...

The Motley Fool - 8 months ago

If you have cash to spare, these cancer stocks are set to soar.

Other stocks mentioned: EPZM
InvestorPlace - 8 months ago

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

Other stocks mentioned: CORT, DVAX, IMGN, KDMN, SUPN, VRTX
Zacks Investment Research - 8 months ago

G1 Therapeutics (GTHX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 9 months ago

- Non-dilutive capital to support commercialization and additional development of trilaciclib - Non-dilutive capital to support commercialization and additional development of trilaciclib

Kiplinger - 9 months ago

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: ATRA, DVAX, FIXX, IMGN, KDMN, VKTX
Seeking Alpha - 9 months ago

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

- Jack Bailey appointed to Board of Directors-  Soma Gupta joins as Chief Commercial Officer-  Company reports inducement grant under Nasdaq Listing Rule 5635 (c)(4)

Seeking Alpha - 1 year ago

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark V...

GlobeNewsWire - 1 year ago

SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX ) announced today a c...

GlobeNewsWire - 1 year ago

RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today reported additional data from...

24/7 Wall Street - 1 year ago

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.

Other stocks mentioned: ACAD, ALEC, AMRN, AVDL, BHC, BIIB, EPZM, MGNX, SYRS
GlobeNewsWire - 1 year ago

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Vel...

Seeking Alpha - 1 year ago

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and confe...

The Motley Fool - 1 year ago

Some investors think the market's been too hard on these drugmakers.

Other stocks mentioned: REGN, KNSA

About GTHX

G1 Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is i... [Read more...]

Industry
Biotechnology
IPO Date
May 17, 2017
CEO
Mark Velleca
Employees
122
Stock Exchange
NASDAQ
Ticker Symbol
GTHX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is 59.00, which is an increase of 152.24% from the latest price.

Price Target
$59.00
(152.24% upside)
Analyst Consensus: Buy